151 related articles for article (PubMed ID: 21132303)
1. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity.
Mielnik P; Chwalinska-Sadowska H; Wiesik-Szewczyk E; Maslinski W; Olesinska M
Rheumatol Int; 2012 Mar; 32(3):639-43. PubMed ID: 21132303
[TBL] [Abstract][Full Text] [Related]
2. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.
Shimizu T; Tomita Y; Son K; Nishinarita S; Sawada S; Horie T
Clin Rheumatol; 2000; 19(5):352-9. PubMed ID: 11055823
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.
Samsonov MY; Nassonov EL; Tilz GP; Geht BM; Demel U; Gurkina GT; Shtutman VZ; Guseva AG; Wachter H; Fuchs D
Br J Rheumatol; 1997 Jun; 36(6):656-60. PubMed ID: 9236675
[TBL] [Abstract][Full Text] [Related]
4. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
[No Abstract] [Full Text] [Related]
5. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.
He L; Shu X; Liu X; Ge Y; Li S; Lu X; Wang G
Mediators Inflamm; 2020; 2020():6243019. PubMed ID: 32774147
[TBL] [Abstract][Full Text] [Related]
6. Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17/Treg immune imbalance.
Xie Y; Zhang T; Su R; Liu L; Jiang L; Xue H; Gao C; Li X; Wang C
Clin Exp Med; 2023 Nov; 23(7):3605-3617. PubMed ID: 37528249
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.
Evereklioglu C; Er H; Türköz Y; Cekmen M
Mediators Inflamm; 2002 Apr; 11(2):87-93. PubMed ID: 12061429
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases.
Shen H; Xia L; Lu J
Cytokine; 2012 Nov; 60(2):334-7. PubMed ID: 22863719
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.
Gabay C; Gay-Croisier F; Roux-Lombard P; Meyer O; Maineti C; Guerne PA; Vischer T; Dayer JM
Arthritis Rheum; 1994 Dec; 37(12):1744-51. PubMed ID: 7986220
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.
Yin L; Ge Y; Yang H; Peng Q; Lu X; Zhang Y; Wang G
Clin Rheumatol; 2016 Nov; 35(11):2715-2721. PubMed ID: 27502600
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.
Liu T; Hou Y; Dai TJ; Yan CZ
Chin Med J (Engl); 2017 Sep; 130(17):2101-2106. PubMed ID: 28836555
[TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection.
Weiss M; Martignoni M; Petropoulou T; Sölder B; Belohradsky BH
Infection; 1996; 24(4):301-8. PubMed ID: 8875282
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis.
Jiang Q; Li Y; Xia L; Shen H; Lu J
J Interferon Cytokine Res; 2019 Nov; 39(11):720-725. PubMed ID: 31274382
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
[TBL] [Abstract][Full Text] [Related]
18. Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.
Son K; Tomita Y; Shimizu T; Nishinarita S; Sawada S; Horie T
Intern Med; 2000 Feb; 39(2):128-35. PubMed ID: 10732829
[TBL] [Abstract][Full Text] [Related]
19. Soluble TNF and IL-2 receptors in patients with breast cancer.
Tesarová P; Kvasnicka J; Umlaufová A; Homolková H; Jirsa M; Tesar V
Med Sci Monit; 2000; 6(4):661-7. PubMed ID: 11208388
[TBL] [Abstract][Full Text] [Related]
20. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.
Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H
Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
